Frontiers in Oncology (May 2023)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

  • Shuqi Xie,
  • Mengchao Wang,
  • Chuanxiu Zeng,
  • Yan Ou,
  • Lu Zhao,
  • Dong Wang,
  • Liwei Chen,
  • Fanming Kong,
  • Dan Yi

DOI
https://doi.org/10.3389/fonc.2023.1197698
Journal volume & issue
Vol. 13

Abstract

Read online

Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma and discusses the effectiveness and safety of the combination of the two drugs to provide a reference for the further application of molecular-targeted drugs combined with immune checkpoint inhibitors in clinical practice.

Keywords